Search
-
FDA approves Flonase allergy relief for sale over-the-counter in the United States
Media
No. 1 prescribed allergy treatment ingredient1 to be available OTC
https://www.gsk.com/en-gb/media/press-releases/fda-approves-flonase-allergy-relief-for-sale-over-the-counter-in-the-united-states/
First published: 24 July 2014
-
Regulatory update on three-part transaction with Novartis
Media
GlaxoSmithKline plc (GSK) has today received clearance from the European Commission of its proposed three-part transaction with Novartis
https://www.gsk.com/en-gb/media/press-releases/regulatory-update-on-three-part-transaction-with-novartis/
First published: 28 January 2015
-
GSK receives EU marketing authorisation for Incruse (umeclidinium) for the treatment of COPD
Media
GlaxoSmithKline plc (LSE/NYSE: GSK) announced today that the European Commission has granted marketing authorisation for Incruse®
https://www.gsk.com/en-gb/media/press-releases/gsk-receives-eu-marketing-authorisation-for-incruse-umeclidinium-for-the-treatment-of-copd/
First published: 28 April 2014
-
GSK receives positive opinion from the CHMP in Europe for once-weekly EperzanTM (albiglutide) for the treatment of type 2 diabetes
Media
GlaxoSmithKline plc today announced that the Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion albiglutide
https://www.gsk.com/en-gb/media/press-releases/gsk-receives-positive-opinion-from-the-chmp-in-europe-for-once-weekly-eperzantm-albiglutide-for-the-treatment-of-type-2-diabetes/
First published: 24 January 2014
-
GSK commits further funding to advance bioelectronics research with creation of 5 million Innovation Challenge Fund
Media
GSK announced, $5 million ICF to encourage and advance collaborative research as part of its effort to develop bioelectronic medicines.
https://www.gsk.com/en-gb/media/press-releases/gsk-commits-further-funding-to-advance-bioelectronics-research-with-creation-of-5-million-innovation-challenge-fund/
First published: 30 September 2014
-
Stiefel, a GSK company, announces start of phase III study of subcutaneous ofatumumab for pemphigus vulgaris
Media
Stiefel, announced phase III study to evaluate the efficacy and safety of subcutaneous ofatumumab in patients with pemphigus vulgaris
https://www.gsk.com/en-gb/media/press-releases/stiefel-a-gsk-company-announces-start-of-phase-iii-study-of-subcutaneous-ofatumumab-for-pemphigus-vulgaris/
First published: 07 October 2014
-
Publication of Circular and Notice of General Meeting relating to the proposed major transaction with Novartis
Media
GSK announced a major conditional transaction with Novartis involving its Consumer Healthcare, Vaccines and Oncology businesses
https://www.gsk.com/en-gb/media/press-releases/publication-of-circular-and-notice-of-general-meeting-relating-to-the-proposed-major-transaction-with-novartis/
First published: 24 November 2014
-
GSK receives approval for Incruse™ Ellipta® (umeclidinium) in the US for the treatment of COPD
Media
GSK announced that the FDA has approved umeclidinium as treatment of airflow obstruction in patients with COPD.
https://www.gsk.com/en-gb/media/press-releases/gsk-receives-approval-for-incruse-ellipta-umeclidinium-in-the-us-for-the-treatment-of-copd/
First published: 30 April 2014
-
ViiV Healthcare announces start of phase III study evaluating long-acting cabotegravir for HIV prevention
Media
First injectable to be studied for efficacy in pre-exposure prophylaxis
https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-start-of-phase-iii-study-evaluating-long-acting-cabotegravir-for-hiv-prevention/
First published: 20 December 2016
-
GSK leads Access to Medicine Index 2016
Media
GSK has today been ranked first in the Access to Medicine Index for the fifth consecutive time.
https://www.gsk.com/en-gb/media/press-releases/gsk-leads-access-to-medicine-index-2016/
First published: 14 November 2016